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Abstract
Nutrition is an important factor in the primary and secondary prevention of cardiovascular
disease. Cardiovascular disease is the leading cause of death in North America and the world.
Observational studies have generally favoured a beneficial role of n-3 fatty acids in the preven-
tion of heart disease, especially in the prevention of sudden cardiac death. The results of more
recent randomised controlled studies, however, have made conclusions regarding the benefit
more controversial, with the suggestion of possible harm with fish oil supplementation to those
with diagnosed cardiovascular disease.
We provide an overview of the results of studies to date and introduce the controversial topics of
the omega-6/omega-3 ratio, the public’s concerns regarding ingestion of mercury from marine
n-3 sources and the potential role of highly bioactive n-3 metabolites in the process of athero-
sclerosis. We also provide some general guidelines for the ingestion of n-3 fatty acids that may
help clinicians and patients make informed decisions. (Folia Cardiol. 2006; 13: 557–569)
Key words: omega-3 fatty acids, omega-6 fatty acids, n-6/n-3 ratio, omacor,
omega-3 index
Introduction
Omega-3 fatty acids (n-3s) are essential com-
ponents of human nutrition as they cannot be in-
ternally synthesised in amounts sufficient for health
[1]. Omega-3 fatty acids are a group of polyunsatu-
rated fats in the human diet with the first double
bond at the 3rd carbon–carbon bond from the termi-
nal methyl end (w) of the carbon chain, from which
is derived their nomenclature designation as “n-3”
fatty acids. These fatty acids concentrate in high
amounts in metabolically active tissues, including
the myocardium, brain, retina, and testes. Alpha-
-linolenic acid (ALA) is found in plant sources,
whereas the important long chain omega-3 fatty
acids, eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA), are found in the tissues of ma-
rine animals. Alpha-linolenic acid [ALA (18 3n-3)]
is the omega-3 fatty acid ingested in the greatest
amount in a typical diet, given its prevalence in
commonly consumed plant oils, including canola
(rapeseed) and flax seed. ALA has demonstrated
conversion into eicosapentaenoic acid [EPA (20 5n-3)]
and docosahexaenoic acid [DHA (22 6n-3)], although
evidence suggests that this pathway may not produce
amounts adequate for attaining optimal health [1].
The fish-derived n-3 fatty acids are of greatest in-
terest as they have been correlated with cardiovas-
cular disease more consistently than has ALA.
Cardiovascular disease is the leading cause of
death among adults in the United States, with an
estimated 910,000 individuals dying from this
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disease in 2003 [2]. Heart disease is predicted to
grow in importance with respect to public health as
medical advances allow individuals to live much
longer than they did just 30 years ago. Attempts to
reduce the public health burden of heart disease
have enlisted numerous methods, including lifestyle
modifications, medications and a variety of expen-
sive technologies. Nutritional modifications that
alter the risk of cardiovascular disease have been
a major focus of intervention efforts, as reflected in
numerous studies and expert consensus panel rec-
ommendations. Saturated fat and cholesterol have
been of particular interest owing to their wide preva-
lence in modern western diets and well documented
roles in the process of atherosclerosis. Omega-3
fatty acids, particularly those derived from marine
sources, have also been of great interest because
of their unique biochemical and physiological prop-
erties. Although many of the benefits of omega-3
fatty acids for cardiovascular health remain contro-
versial, new information about how they affect
arterial endothelial function, haemodynamics (car-
diac mechanics) and cardiac myocyte function (in-
cluding anti-arrhythmic effects), have improved our
understanding of their possible mechanisms of ac-
tion. The omega-6 (n-6) class of fatty acids, on the
other hand, compose a counteracting branch in the
fatty acid pathway that compete with the n-3 anti-
-inflammatory compounds in the enzymatic pathway
necessary to create biologically active molecules [3].
It has been suggested that a lower ratio of dietary
n-6 to n-3 fatty acids promotes health and that this
ratio in the human diet has significantly increased
over the millennia [3, 4]. Controversies have aris-
en regarding the relative benefits of omega-6 vs.
omega-3 fatty acids (the omega-6/omega-3 ratio) as
well as the safety of fish and fish oil supplement
consumption. At the same time, metabolites of
omega-3 fatty acids are now being considered as
possible anti-inflammatory mediators in the proc-
ess of protecting against atherosclerosis.
Possible mechanisms of action
Effects on lipid metabolism
N-3 fatty acids can reduce fasting and postpran-
dial triglyceride concentrations by 20–35% by ac-
celerating chylomicron triglyceride clearance and
suppressing hepatic very low-density lipoprotein
(VLDL)-triglyceride production [5]. Evidence sug-
gests that they also modulate the susceptibility of
VLDL to lipolysis [6, 7]. Concerns have been ex-
pressed regarding the fact that omega-3 fatty acids
tend to raise low-density lipoprotein (LDL) and may
predispose to lipid oxidation. These concerns, how-
ever, appear to be outweighed by evidence in sup-
port of a cardioprotective effect of n-3 fatty acids
[5, 8, 9]. Current evidence reveals that omega-3
fatty acids tend to raise high-density lipoprotein
(HDL) slightly in most individuals, but n-3 effects
on HDL are not felt to play a significant role in car-
diovascular risk reduction [10].
Anti-inflammatory effects
The anti-inflammatory effects of omega-3 fat-
ty acids on the cardiovascular system are contro-
versial [11]. Data from the Diet and N-3 Interven-
tion Trial (DOIT) revealed that a three-year diet
and/or n-3 supplementation period in elderly males
(mean age 70 years) with hyperlipidaemia did not
consistently improve several markers of endothe-
lial activation including soluble vascular adhesion
molecule and von Willebrand’s factor [12]. Fish in-
take has also not correlated well with C-reactive
protein, intercellular adhesion molecules and inter-
leukin-6 [13]. Other studies have added to the con-
troversy by either revealing a direct effect [14] or
no effect on inflammatory markers [15]. The spe-
cific effects of inflammation on the risk of ventricu-
lar tachycardia/ventricular fibrillation and sudden
cardiac death are unclear.
Inhibition of thrombosis
Inhibition of thrombosis is a mechanism by
which n-3 fatty acids appear to exert a protective
effect within the cardiovascular system. EPA inhib-
its the formation of the prothrombotic eicosanoid
thromboxane A2 by competing with arachidonic acid
for the cyclo-oxygenase enzyme [16]. N-3 fatty ac-
ids also inhibit platelet adhesion, platelet aggrega-
tion, and the formation of thromboxane B2, another
prothrombotic cytokine. In the Thrombogenic Fac-
tors and Recurrent Coronary Events (THROMBO)
study [17], of six haemostatic factors, 7 lipid meas-
ures, and insulin, D-dimer, apoA and apoB were
identified as independently predicting recurrent
ischaemic events. Although omega-3 fatty acid sup-
plementation has been associated with lower
D-dimer levels in subjects without heart disease [18],
no consistent relationship has been demonstrated
for n-3 effects on these two other prothrombotic
variables.
Attenuation of tissue
hypertrophy and fibrosis
N-3 fatty acids appear to attenuate tissue
hypertrophy and fibrosis within the cardiovascular
system. They have, for example, been demonstrated
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to inhibit the adverse effects of angiotensin II on
vascular smooth muscle [19]. If similar metabolic
effects occur in myocardial tissue, the hypertroph-
ic effects of angiotensin II may be inhibited [20]. The
benefits of inhibiting angiotensin II has been dem-
onstrated through the ability of ACE inhibitors to
inhibit fibrotic hypertrophy and improve survival in
affected individuals [21–25].
Anti-arrhythmic effects
Since the mid-1970s an anti-arrhythmic effect
of n-3 fatty acids has been investigated, with evi-
dence that ALA increased the arrhythmia thresh-
old [26, 27]. A variety of animal model studies have
revealed a reduction in arrhythmic events, includ-
ing important investigations conducted by Billman
et al. [28]. In these studies, exercise-induced ven-
tricular fibrillation in an ischaemic heart disease dog
model was prevented in animals infused with an
emulsion of n-3 fatty acids. A variety of in vitro and
animal experiments have revealed that omega-3
fatty acids may exert anti-arrhythmic effects by di-
rectly modulating potassium, sodium, and calcium
channels [29]. These fatty acids also incorporate
into the phospholipids of cell membranes, modulat-
ing the excitation-coupling that can result in ar-
rhythmia [30] and can affect the intracellular en-
zymes which control the contraction and relaxation
cycles of myocytes [31]. N-3 fatty acids also tend
to inhibit ventricular arrhythmias by blocking the
effects of catecholamines on the myocardium, sim-
ilar to beta-blockade [32]. They apparently accom-
plish this by affecting the adrenoceptors, which are
membrane proteins that allow the neuroendocrine
messages of catecholamines to transmit to the
myocardium.
Modulating arterial compliance, heart rate
variability, and ventricular function
N-3 fatty acids have been shown to improve
arterial compliance in response to physiological
stressors [33]. Omega-3 fatty acids have also been
demonstrated to improve baseline arterial compli-
ance [34]. Heart rate variability (HRV) is an accept-
ed measure of cardiovascular health as normal HRV
reflects increased parasympathetic tone [35]. Op-
timal HRV can subsequently increase the ventricu-
lar fibrillation threshold and thus protect the myo-
cardium from ventricular arrhythmias. Notable is
the fact that beta-blockers and angiotensin-convert-
ing enzyme inhibitors, which improve long term
survival in those with heart failure, also improve
heart rate variability [36]. At least two studies, one
involving a post-myocardial infarction cohort, have
revealed improved heart rate variability in subjects
exposed to supplemental sources of n-3 fatty acids,
with one also demonstrating improved ventricular
compliance [37, 38]. A higher dietary fish intake has
also been independently associated with lower heart
rates, reduced systemic vascular resistance, left
ventricular mass and greater stroke volume [39].
Primary prevention
Investigations of the role of omega-3 fatty ac-
ids in primary prevention studies have been limit-
ed to epidemiological and observational studies
(Table 1). Three early prospective observational
studies reported that men consuming at least some
fish every week had a lower mortality rate from
coronary artery disease (CHD) than those men who
ate no fish weekly [40]. More recently, the Chica-
go Western Electric Study found that men who
Table 1. Major primary prevention/observational studies.
Study Year Subjects Results (with higher fish intake)
Health Professionals Follow-Up 1995 44,895 men No reduction in fatal CHD,
non-fatal MI, SCD, CABG, PTCA
Seven Countries 1996 12,763 men No reduction in CHD death
Western Electric 1997 1,822 men Reduced total CHD and non-sudden CHD death
US Physicians’ Health 1998 20,551 men Reduced total mortality and SCD.
No reduction in non-sudden CHD death,
CHD mortality or total MI
Nurses’ Health 2002 84,688 women Reduced risk of CHD and CHD mortality.
No reduction in non-fatal MI
EUROASPIRE 2003 415 (285 men, Reduced total and CHD mortality
130 women)
CHD — coronary heart disease, MI — myocardial infarction, SCD — sudden cardiac death, CABG — coronary artery bypass grafting, PTCA — percu-
taneous transluminal coronary angioplasty
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consumed 35 g of fish or more daily had a relative
risk of CHD death of 0.62 and a relative risk of non-
sudden death from myocardial infarction (MI) of
0.33 compared with men who consumed no fish [41].
An ecological study including data from 36 countries
found that fish consumption was associated with
a reduced risk of ischaemic heart disease, stroke and
all-cause mortality [42]. A recent analysis focusing
on women’s health within the Nurses’ Health Study
documented an inverse correlation between fish in-
take and omega-3 fatty acids and CHD death [43].
In that study, women consuming fish from once to
three times per month, once per week, from two to
four times per week and > five times per week had
a risk for CHD death that was 21%, 29%, 31%, and
34% lower respectively than women who ate fish
less than once per month.
Other observational studies have not demon-
strated reduced CHD mortality associated with
fish consumption. In the US Physicians’ Health
Study, no significant association was observed
between fish intake (or omega-3 intake consump-
tion) and a reduced risk of non-sudden cardiac
death, total cardiovascular mortality or total MI
[44]. In this study fish consumption was associat-
ed with total mortality, however. Similarly, in the
Health Professionals’ Follow-up Study, risk of any
CHD (non-fatal MI, coronary artery bypass graft-
ing, angioplasty or fatal coronary disease, includ-
ing sudden cardiac death) was not associated with
fish consumption (and omega-3 fatty acids) [45].
In the Seven Countries Study, despite the pres-
ence of an inverse relationship between fish con-
sumption and 25-year mortality from CHD across
several populations, this association was not sig-
nificant when the relationship was adjusted for
the effects of flavonoids, smoking and saturated
fat [46].
Biomarkers of fatty acid intake, including adi-
pose tissue and plasma levels, have inconsistently
been associated with the risk of coronary heart
events. Several case-control and cohort studies have
demonstrated that high levels of n-3 fatty acids are
associated with a reduced risk of acute MI [47–50],
primary cardiac arrest [51] and sudden cardiac death
[52]. No association between biomarkers of n-3 poly-
unsaturated fatty acids (PUFA) and acute coronary
syndromes has been found in other studies, however
[53–56].
A variety of explanations for the conflicting
observational data have been proposed [1]. These
include variability in the end points studied, study
populations, how fish intake was estimated or the
experimental design, confounding of reference
groups who had an unhealthy lifestyle, and differ-
ences in sudden cardiac death definitions. Only
studies that included a large population of non-fish-
eating individuals have reported an inverse corre-
lation of fish consumption with coronary disease
mortality. Other explanations considered are that
only eating fatty fish can provide the levels of ome-
ga-3 fatty acids required to provide protection and
that only those populations at high risk benefit from
a reduction in CHD mortality.
The evidence of benefit in reducing risk of sud-
den cardiac death is more consistent. A report from
the US Physicians’ Health Study found that the rel-
ative risk of sudden death in men without a history
of cardiovascular disease (CVD) was significantly re-
duced in men with omega-3 blood levels in the third
quartile (RR = 0.28) and fourth quartile (RR = 0.19)
when compared to men with blood levels in the low-
est quartile [52]. A prior analysis within the same
cohort demonstrated that men consuming fish at
least once each week had a relative risk of sudden
death of 0.48 (p = 0.04) compared to men consum-
ing fish less than once each month [44]. Finally, in
another nested, case-control population-based
study fish consumption equivalent to two fatty fish
meals each week was associated with a 50% reduc-
tion in risk for primary cardiac arrest [51].
Secondary prevention
The majority of investigations of the role of n-
3 fatty acids in secondary prevention of heart disease
have been randomised controlled trials (Table 2). In
the Diet and Reinfarction Trial (DART), men after
an MI were randomised to increased dietary intake
of fish (200–400 g of fatty fish per week, correlating
with 500–800 mg/d of omega-3 fatty acids) and
showed a 29% reduced incidence of all-cause mor-
tality [4]. The benefits were largest in the preven-
tion of fatal MIs, leading to a hypothesis that n-3
fatty acids protect the myocardium from the adverse
consequences of ischaemic stress. In the Lyon
Heart Study post-MI individuals advised to eat a diet
high in alpha-linolenic acid had a greatly reduced
incidence of cardiovascular mortality, total mortal-
ity, recurrent MI, stroke, unstable angina and heart
failure [57]. The Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto miocarico (GISSI)-Pre-
vention Study was the largest trial testing the effi-
cacy of omega-3 fatty acids for secondary preven-
tion [58]. This study of individuals with a recent MI
(< 3 months) demonstrated that 850 mg/d of ome-
ga-3 supplementation reduced all-cause mortality
after a MI, with a 15% reduction in the primary end
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point of non-fatal MI, non-fatal stroke and death
(p < 0.001). A 20% reduction in all-cause mortality
(p = 0.01) and a 45% reduction in sudden death
(p < 0.001) occurred in comparison with the control
group. An analysis of follow-up data from GISSI
revealed that the survival curves for those ran-
domised to take or not take omega-3 supplements
diverged at only three months [59]. Although this
was a very large trial in which patients received
routine post-MI care, a limitation is that it was not
placebo-controlled.
Some recent studies have not shown a benefit
for omega-3 fatty acids in the realm of secondary
prevention. In DART-2 men with stable angina pec-
toris were randomised to a recommendation to eat two
fatty fish meals each week or no change in diet [60].
Those who could not consume this much fish were
supplemented with 3 g of fish oil per day. The risk
of sudden cardiac death, interestingly, was increased
in those randomised to increased n-3 intake (hazard
ratio = 1.54), particularly in those recommended to
take supplements (hazard ratio = 1.84).
In another trial 300 patients after an acute MI
were randomised to either 3.5 g of EPA + DHA or
corn oil and followed for an average of 1.5 years [61].
No significant difference was demonstrated in sin-
gle or combined events of unstable angina, recur-
rent MI, resuscitation or cardiac death. As this study
was conducted in western Norway, its authors spec-
ulated that the high habitual fish consumption in the
region may have already provided a benefit in those
with the lowest levels of omega-3 fatty acid con-
sumption, minimising the presence of a dose-de-
pendent effect.
In the EUROASPIRE study of 285 men and
130 women with established CHD the relative risks
for death, adjusted for CHD risk factors, for those
with the highest tertile of serum omega-3 fatty ac-
ids, were 0.33 for ALA, 0.33 for EPA and 0.31 for
DHA [62]. A high proportion of EPA was associat-
ed with a reduced risk of CHD death and, compared
with no omega-3 fatty acid consumption, fish intake
tended to be associated with a lower risk of death
(p for trend = 0.059). In the large international case-
control EURAMIC Study adipose tissue DHA
(a measure of long-term fish intake) was not asso-
ciated with risk of MI [53].
The benefits of n-3 fatty acids in reducing angio-
graphic progression are controversial. Sacks et al. [63]
randomised patients with angiographically docu-
mented CHD and normal plasma lipid levels to re-
ceive either 6 g of n-3 fatty acids (n = 31), or olive
oil (n = 28) for a mean duration of 28 months. Fish
oil lowered triglyceride levels 30% (p = 0.007), had
no effects on other plasma lipoprotein levels and did
not promote major favourable changes in the diam-
eter of atherosclerotic coronary arteries (p = 0.8).
Von Schacky et al. [64] randomised 223 patients
with angiographically documented coronary artery
disease to fish oil concentrate or placebo with a fat
composition resembling that of the average European
diet for a total of 24 months. At the end of treatment
a significant difference in the number of vessels with
documented change in luminal diameter was noted
Table 2. Major secondary prevention/intervention studies.
Study Year Subjects Intervention Outcome (with higher n-3 intake)
DART 1989 2033 men Dietary fish Reduced total mortality and fatal MI
Lyon Heart Study 1994 605 men High-ALA Reduced CHD, total mortality,
and women  Mediterranean diet  recurrent MI, stroke,
unstable angina and CHF
GISSI 1999 11,323 men n-3 Reduced total mortality,
and women supplement  combined end point of non-fatal MI,
non-fatal stroke and death
Nilsen et al. 2001 300 n-3 No reduction in MI, SCD or
supplement  non-SCD, unstable angina
DART-2 2003 3114 men Dietary fish or Increased risk of SCD
n-3 supplement
Raitt et al. 2005 200 men n-3 No significant change
and women supplement  in ventricular arrhythmias
FAAT 2005 402 men n-3 Marginal reduction in ventricular
and women supplement arrhythmias or total death
SOFA 2006 546 men n-3 No change in ventricular arrhythmias
and women supplement  or total mortality
MI — myocardial infarction, CHD — coronary heart disease, CHF — coronary heart failure, SCD — sudden cardiac death
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between the fish oil and placebo groups (p = 0.041).
Losses in minimal luminal diameter were somewhat
less in the fish oil group (p > 0.1) and fish oil recip-
ients had fewer cardiovascular events (p = 0.10);
other clinical variables did not differ between the
study groups [64]. Eritsland et al. [65] randomised
610 patients undergoing coronary artery bypass
grafting to either 4 g/d of fish oil concentrate per
day or to a control group. The primary end point was
one-year graft patency, assessed angiographically,
and vein graft occlusion rates were 27% in the fish
oil group and 33% in the control group (odds ratio =
= 0.77, p = 0.034). In the fish oil group fewer sub-
jects had > or = 1 occluded vein graft(s) compared
with the control group (odds ratio = 0.72, p = 0.05).
Most importantly, a significant trend of fewer pa-
tients with vein graft occlusions with increasing
relative change in serum phospholipid n-3 fatty ac-
ids existed (p for linear trend = 0.0037).
Arrhythmia prevention in those
with cardiomyopathy
The anti-arrhythmic effects of omega-3 fatty
acids in individuals with cardiomyopathy are un-
clear. In a recently published trial by Raitt et al. [66]
subjects with cardiomyopathy, an implantable car-
dioverter defibrillator (AICD) and a recent episode
of ventricular tachycardia or ventricular defibrilla-
tion were randomised to 1.3 g/d of omega-3 fats or
placebo. The supplements did not prevent arrhyth-
mias and actually demonstrated a decrease in time
to recurrent VT/VF in those with a history of ventricu-
lar tachycardia. This increase was not, however,
statistically significant. Total and cardiac mortality
were, however, lower in the fish oil compared to
the placebo group, although this difference was not
statistically significant. In subgroup analyses sub-
jects with ventricular fibrillation at entry and those
with non-ischaemic cardiomyopathy had, in compar-
ison with those with ischaemic disease, a longer
shock-free interval with omega-3 fatty acid supple-
mentation. The average left ventricular ejection
fraction (LVEF) in this study was 35%, significant-
ly better than 23% in the Multi-center Automatic
Implantable Defibrillator Trial-II, where LVEF was
shown to be associated with AICD activation and
post-enrolment heart failure [67]. The improved
LVEF in the Raitt study [66] may have limited the
effects of omega-3 fatty acids on ventricular arrhyth-
mias. Notable also is the fact that the “survival”
curves of time-to-AICD activation for the supple-
mented and non-supplemented groups converged
~650 days after randomisation in those at higher
risk of sudden cardiac death (LVEF < 40%), where-
as they remained quite disparate in those with an
LVEF > 40%. A limitation of this study is the fact
that there was only 70% power to detect the antic-
ipated differential in the rate of VT/VF between the
two groups owing to the lack of events. The findings
could, therefore, have been related to chance alone
or to an undetected risk modifier. Leaf et al. [68],
in the Fatty Acid Anti-arrhythmic Trial (FAAT),
randomised subjects with an AICD to either 4 g per
day of fish oil supplement or an olive oil placebo and
recorded the number of therapeutic discharges or
fatal arrhythmias. Eligible patients for this study
were those with an AICD implanted for a prior ep-
isode of cardiac arrest from VF or sustained VT, or
for syncope with inducible sustained VT or VF.
Assignment to treatment with fish oil showed
a trend to a prolonged time to the first AICD event
(VT or VF) or to death from any aetiology (RR = 0.72,
p = 0.057). When AICD therapies for probable
events were included, the reduction in risk became
statistically significant (RR = 0.69, p = 0.033). For
those with confirmed events the anti-arrhythmic
benefits of fish oil were improved if the subject re-
mained on the protocol for at least 11 months. The
Study on Omega-3 Fatty Acids and Ventricular Ar-
rhythmia (SOFA) has been the most recent to in-
vestigate the effects of omega-3 fatty acids in pre-
venting arrhythmia in those with an AICD [69]. In
SOFA patients with an AICD and a prior document-
ed episode of ventricular fibrillation or malignant
ventricular tachycardia were randomly assigned to
take 2 g/d of fish oil or placebo. The main end point
of appropriate AICD intervention for VT or VF or
all-cause mortality did not differ significantly be-
tween the groups. This lack of benefit from omega-
3 supplementation was also noted in subgroups of
patients with a prior MI or those who had experi-
enced VT within the year before the study.
The Raitt et al., FAAT, and SOFA studies do
not suggest a consistent benefit from omega-3 fat-
ty acids in the prevention of ventricular arrhythmi-
as and sudden cardiac death in those with cardio-
myopathy. A dose effect may be present, however,
as these trials generally used high dose and phar-
macological-grade (up to 4 g/d) omega-3 supple-
ments, whereas consumption of less than 1 g/d has
been demonstrated to reduce the risk of fatal coro-
nary events [70]. These studies were also essen-
tially secondary sudden death prevention trials, as
they studied subjects with prior sudden cardiac
death, documented spontaneous VT/VF or synco-
pe with inducible VT/VF. Note that prior trials re-
vealing an improved outcome were in the realm of
primary malignant arrhythmia prevention. These
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more recent trials also used arrhythmia as the end
point, whereas experimental studies have used is-
chaemic VF as the end point, and clinical trial and
cohort studies have used sudden death as the out-
come of interest [66]. Prior trials, in addition, have
also focused on individuals with a recent MI and rel-
atively preserved LVEF, whereas these three re-
cent studies have investigated n-3 effects in those
without recent MI, on average a reduced LVEF and
documented VT/VF. The contrast of these studies
with prior investigations may thus be due to differ-
ences in the pathophysiology and severity of heart
disease amongst different study populations. The
major secondary prevention studies are detailed in
Table 2.
Meta-analyses
A recent systematic review assessing the ef-
fects of omega-3 fatty acids on cardiovascular dis-
ease suggests that omega-3 fatty acids may not have
consistent cardioprotective effects. In this meta-
analysis Hooper et al. [71] evaluated 48 randomised
controlled trials that assessed outcome after at least
six months of omega-3 supplementation and 41 co-
hort studies that determined outcome after follow-
up of at least six months. The pooled results of the
trials were inconsistent but with no reduction in
total mortality or cardiovascular events. For those
studies at low risk of bias no reduction in total mor-
tality or cardiovascular events was found. When
analysis was isolated to studies assessing only long-
chain fatty acids, no reduction in the same events
was noted either.
The safety of fish
and omega-3 supplements
Formal recommendations have been made by
the American Heart Association advocating that all
adults eat oily fish as least twice each week and that
patients with documented coronary heart disease
consume approximately 1 g of the two fish-derived
omega-3 fatty acids, eicosapentaenoic acid and do-
cosahexaenoic acid, each day [1]. The U.S. govern-
ment has recommended that non-pregnant adults
consume fish for its nutritional benefits [72]. Con-
cerns regarding the potential adverse health effects
of methylmercury and polychlorinated biphenyl
(PCB) ingestion from fish, however, have prompt-
ed investigations into whether these concerns are
warranted. Fish is a leading source of exposure to
methylmercury and some evidence suggests that
mercury may reduce the beneficial effects of n-3
PUFAs on CHD risk [73]. The Harvard Center for
Risk Analysis recently convened an expert panel to
investigate the aggregate impacts of hypothetical
shifts in fish consumption resulting from these con-
cerns [72]. This panel concluded that if non-preg-
nant adults inappropriately and mistakenly reduce
their fish consumption, the net impact on public
health would be negative. The panel’s findings, in-
stead, suggested that the public should focus on
eating low-mercury fish that tend to be lower on the
food chain. The health benefits of eating salmon in
fact, based on human data and doses typically con-
sumed, are estimated to be at least 100-fold great-
er than the estimates of harm. Although this analy-
sis only included the effects of methylmercury (not
PCBs), the potential health effects of PCBs are con-
sidered to be unlikely to be important in compari-
son with those of mercury. Willett [74], in an ac-
companying editorial article on the fact that fish con-
sumption has decreased in the U.S. owing to health
concerns, notes that this panel’s analysis “high-
lights concerns that educational messages and the
implementation of policies must be carefully craft-
ed to avoid unintended consequences”.
OmacorR is the only pharmaceutical-grade,
FDA approved, omega-3 fatty acid supplement avail-
able in the United States [75, 76]. It is available only
by prescription, 90% composed of the omega-3
ethyl esters EPA and DHA and sold by Reliant Phar-
maceuticals. It is approved at a dose of 4 g/d, for
the treatment of triglyceride levels ≥ 500 mg/dl
in conjunction with lifestyle modification. Through
its patented process Reliant and the FDA have en-
sured that levels of mercury and other pollutants
are not a concern. With regard to over-the-counter
supplements, the FDA has determined that intakes
of marine omega-3 fatty acids up to 3 g/d are GRAS
(Generally Regarded As Safe) [77] and has approved
a qualified health claim for DHA and EPA as die-
tary supplements [78]. The ruling on safety includ-
ed specific consideration of the effects of omega-3
fatty acids in raising LDL cholesterol levels slight-
ly and of their having no demonstrated adverse ef-
fect on glycaemic control in patients with diabetes.
The relevance of the
omega-6/omega-3 ratio
The ratio of n-6 to n-3 fatty acids has intellec-
tual appeal as a predictor for coronary artery events,
given that the ratio of these fatty acids in the hu-
man diet is estimated to have increased over the
millennia from approximately 1:1 to 20–25:1 [79]
and the fact that these two classes of fatty acids
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compete for the same metabolic pathways. Part of
the concern over this metric is the fact that a ratio
can be altered with relative changes in the numera-
tor or the denominator, whereas the total level of n-
6 and n-3 fatty acids may be more important. Fur-
thermore, the ratio includes all n-6 and n-3 fatty ac-
ids and thus does not take into account the fact that
long-chain fatty acids have different physiological
properties from their shorter-chain counterparts.
Epidemiological evidence does not tend to sup-
port an increased risk with a higher n-6/n-3 ratio.
Within the National Heart, Lung, and Blood Insti-
tute’s Family Heart Study the relationship between
dietary linolenic (n-3) and linoleic (n-6) and the
prevalence of atherosclerotic heart disease was
evaluated in 4,584 subjects [80]. In this study lev-
els of both linolenic and linoleic fatty acids, increas-
ing from the lowest to the highest quintiles, were
associated with a reduction in risk (with p values
for trend = 0.014 for men and 0.012 for women,
respectively for linolenic acid). The combined ben-
eficial effect of linoleic and linolenic acids was, in
fact, stronger than the effects of each fatty acid in-
dividually. This suggests that a ratio of fatty acids
that are both beneficial may not be relevant. With-
in the Health Professionals Follow-Up Study [81]
the relationship of fatty acid intake to the incidence
of CHD events was evaluated. The authors specif-
ically investigated whether levels of n-6 fatty acids
attenuated the benefits of n-3 fatty acids. Levels of
intake of both long-chain (EPA, DPA, and DHA) and
intermediate chain n-3 fatty acids (ALA) ≥ the me-
dian were associated with a reduction in risk of
a CHD event, whether n-6 fatty acid consumption
was above or below the median.
Goyens et al. [82] examined the relationship
of dietary ALA and linoleic acid (LA) on serum lipo-
protein subclass distributions and particle sizes in
54 healthy subjects. Each subject consumed a con-
trol diet providing 0.4% of energy (En%) as ALA
and 7 En% as LA during a four-week run-in period.
During a six-week intervention each of 18 subjects
consumed the control diet, a low-LA diet (3 En%
LA, 0.4 En% ALA), or a high-ALA diet (7 En% LA,
1.1 En% ALA). The ALA:LA ratio for the control
diet was 1:19 and was a constant 1:7 for the other
two diets. Compared with that of the control group
LDL cholesterol decreased significantly in the high-
ALA group (–0.32 mmol/L, p = 0.024), as did total
cholesterol, apolipoprotein (apo) B and the total:
HDL cholesterol ratio. In this study, therefore, it
was the total level of ALA, not the ratio of ALA to LA,
which was associated with changes in lipid levels.
In the Nurses’ Health Study and the Health Pro-
fessionals Follow-Up Study, Pischon et al., evaluat-
ed the correlation of fatty acid intake and levels of
serum inflammatory markers [83]. After adjusting for
other predictors of inflammation, intake of the n-3
fatty acids EPA and DHA was inversely associated
with levels of tumour necrosis factor (p < 0.05) and
somewhat less so for C-reactive protein (p = 0.08).
Little if any association of n-3 fatty acid (EPA +
+ DHA) intake with tumour necrosis factor recep-
tors was found among participants with low intake of
n-6 but a strong inverse association was noted
amongst those with a high n-6 intake (p = 0.04). These
data suggest that n-6 fatty acids do not inhibit the ben-
eficial effects of n-3 fatty acids and that, in fact, a com-
bination of both types of fatty acid may be associated
with the lowest risk of cardiovascular disease.
The omega-3 index
Sudden cardiac death (SCD) is one of the lead-
ing causes of death in developed nations [84]. In the
United States the Centers for Disease Control and
Prevention estimates an annual incidence of
450,000 sudden deaths, with a survival rate of 5%.
Despite a reduction in total cardiac mortality from
1989 to 1999, the proportion attributed to SCD in-
creased from 38% to 47%. In absolute terms, SCD
accounts for more annual deaths than breast can-
cer, lung cancer, stroke and AIDS combined. It is
the first presentation of heart disease in 33% to 50%
of patients and is three times more common in men
than women. The ability of n-3 blood level quantifi-
cation to predict cardiovascular events has been of
interest, given that predicting sudden cardiac death
can be quite challenging. Two authors have ex-
plored the potential benefits of measuring red blood
cell phospholipid membrane n-3 levels as a propor-
tion of total fatty acids (an omega-3 index) as a pre-
dictor of death from cardiovascular disease [85].
They conducted laboratory and clinical experiments
to produce the data required to validate the ome-
ga-3 index as a CHD predictor. The correlation of
this putative marker with risk for CHD death, par-
ticularly SCD, was subsequently investigated in
several published primary and secondary preven-
tion studies. Their results demonstrated an inverse
association with CHD death, particularly a dose-
response reduction in risk for SCD that was supe-
rior to that for CRP, homocysteine, total cholester-
ol, LDL, HDL, triglycerides and the total choles-
terol/HDL ratio. These data suggest that the
omega-3 index may be an easily modifiable, inde-
pendent, graded and novel risk factor for sudden
cardiac death and total CHD mortality.
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Omega-3 fatty acid metabolites
Weylandt and Kang [86] commented in “The
Lancet” in 2005 that “to fully understand the rela-
tive contributions of omega-3 and omega-6 fatty
acids in lipid-mediator cascades, several steps are
now necessary: more mediators derived from ome-
ga-3 fatty acids need to be identified and character-
ised; the synthesis pathways for these mediators
and their regulation need to be analysed; the mo-
lecular targets of the mediators need to be under-
stood; and the effects of non-steroidal anti-inflam-
matory drugs and others on these pathways need
to be analysed” (Fig. 1) [3]. Serhan et al. [87] have
discovered that EPA and DHA are the precursors
to potent bioactive mediators which possess both
protective and anti-inflammatory properties. These
mediators have been termed resolvins, protectins
and docosatrienes. Resolvins have been identified
during the resolution phase of acute inflammation
and are synthesised by human cells via cell-to-cell
interactions. Aspirin affects the pathways identified
Figure 1. Omega-3 and omega-6 metabolites. Omega-3 and omega-6 essential fatty acids and some of their metabo-
lites and biological effects. COX — cyclo-oxygenases, LO — lipoxygenases. Prostaglandins (PG), thromboxanes (Tx),
leukotrienes (LT), lipoxins (LX), resolvins (Rv), docosatrienes (DT) and aspirin-triggered lipoxins (ATL) are shown
with their respective abbreviations. Underlined are those mediators for which specific receptors have been identi-
fied. From [86].
as contributing to the synthesis of these fatty acid
metabolites by triggering the formation of their
epimers. Although the clinical implications of these
newly identified compounds are yet to be deter-
mined, their anti-inflammatory and protective prop-
erties may have widespread implications.
Conclusions
The evidence supports the recommendations
of the US government and the American Heart As-
sociation that non-pregnant adults consume oily fish
as part of a well-balanced diet, and should substi-
tute fish relatively low in harmful contaminants,
such as salmon and chunk light tuna, for those high
in contaminants, including king mackerel, shark,
and tilefish. For those individuals without cardio-
vascular disease the benefits of consuming fish
outweigh the potential harm and may significantly
reduce the risk of sudden cardiac death. For those
with diagnosed CVD the evidence is less consist-
ent, but, overall, suggests that the American Heart
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Association’s recommendation to consume 1 g of
EPA and DHA each day may be beneficial. The ev-
idence from DART-2, however, is cause for concern
and suggests that further research is needed to
understand the factors that determine benefit for
those with CVD. For patients at high risk of malig-
nant ventricular arrhythmias further research will
also be required to understand why n-3 fatty acids
demonstrate an anti-arrhythmic effect in experimen-
tal studies but not in individuals with cardiomyopa-
thy, who often have comorbidities and take several
medications. The challenge may be to define the
roles of highly bioactive fatty acid metabolites, of-
ten formed in the presence of aspirin, in the process
of atherosclerosis and in determining clinical out-
comes. Our conclusions regarding n-3 intake made
on the basis of current data are set out in Table 3.
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